China Today: Biogenerics in China: An Evolving Industry - China's large domestic market potential and its competence in producing biogenerics are driving its future direction - BioPharm International

ADVERTISEMENT

China Today: Biogenerics in China: An Evolving Industry
China's large domestic market potential and its competence in producing biogenerics are driving its future direction


BioPharm International
Volume 20, Issue 6

To assure continued industry growth, Chinese authorities recognize the importance of enhancing their country's IP protection systems for both domestic and foreign biologics. The fact that Chinese companies are using the court systems and lawsuits to seek remedies indicates a major change in the Chinese pharmaceuticals business environment. China's large domestic market potential and its solid competence in producing biogenerics are key factors driving its future direction.

REFERENCES:

1. The journey of generic drugs to overturn innovative drugs (in Chinese). Medicine Economic News. 2004; Dec. 30.

2. http:// http://www.oecd.org/document/25/0,2340,en_2649_201185_34967193_1_1_1_1,00.html.

3. http:// http://www.sfda.gov.cn/cmsweb/webportal/W4291/A64003794.html.

4. China's bio-tech and industry appears rapid expansion trend. A report (in Chinese). 2006; Apr. 22. Available at http:// http://www.chinabgao.com/freereports/10264.html.

5. Rader R. Biopharmaceutical products in US and European markets. 5th Ed. BioPlan Associates, Inc. 2006.

Eric Langer is president of BioPlan Associates, Rockville, MD, 301.921.9074.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here